MARKET

LGVN

LGVN

Longeveron Inc
NASDAQ
1.100
0.000
0.00%
After Hours: 1.100 0 0.00% 19:37 04/17 EDT
OPEN
1.110
PREV CLOSE
1.100
HIGH
1.140
LOW
1.080
VOLUME
920.17K
TURNOVER
--
52 WEEK HIGH
1.830
52 WEEK LOW
0.4750
MARKET CAP
25.59M
P/E (TTM)
-0.8516
1D
5D
1M
3M
1Y
5Y
1D
Analysts Are Bullish on These Healthcare Stocks: ARS Pharmaceuticals (SPRY), Longeveron (LGVN)
TipRanks · 4d ago
Weekly Report: what happened at LGVN last week (0406-0410)?
Weekly Report · 5d ago
Longeveron Restores Executive Pay After Recent Financing
TipRanks · 04/10 21:33
LONGEVERON INC - BOARD APPROVES 250,000 RSU GRANT TO EXECUTIVES, 500,000 RSUS TO CEO - SEC FILING
Reuters · 04/10 20:50
Longeveron grants CEO 500,000 RSUs, executives 250,000 after financing closes
Reuters · 04/10 20:49
Longeveron Files Prospectus Related To Resale Of 30.865M Shares By Selling Stockholder
Benzinga · 04/10 20:10
LONGEVERON: PROSPECTUS FILED FOR RESALE OF UP TO 30.9 MLN CLASS A COMMON SHARES BY SELLING STOCKHOLDERS- SEC FILING
Reuters · 04/10 20:05
Longeveron files to sell 30.87M shares of Class A common stock for holders
TipRanks · 04/10 20:05
More
About LGVN
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.

Webull offers Longeveron Inc stock information, including NASDAQ: LGVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LGVN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LGVN stock methods without spending real money on the virtual paper trading platform.